Turns out 2012 was a relatively solid year there, too. Up rounds outpaced down rounds 52% to 17% over the 12 months, with 31% of deals holding steady on valuation, according to study from Fenwick & West. This is a modest improvement from 2011 when 47% of venture capital health care deals were up rounds and 25% saw valuations decline.
Fenwick & West said it analyzed 363 financings in its 2012 Life Science Venture Capital Survey.
Overall, the study found an average 23% increase in private company share price in 2012, a step up from the 14% increase in 2011.
The life-sciences funding environment remains difficult. But perhaps venture capitalists are more confident about the companies they do fund.
Photo courtesy of Shutterstock.